Early prediction of endocrine responsiveness in ER+/HER2 negative MBC: Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.Alessandra Gennari, Nadia Harbeck, Andrea De Censi et al.|Journal of Clinical Oncology|2023Cited by 2